BPC-157 + MOTS-c + 5-Amino-1MQ + Tesamorelin - Kali

1 Identity

Fixed-ratio four-component article and not A peptide blend — three peptides co-lyophilized with a quaternized aromatic bicyclic heterocycle. with the third component also written 5-amino-1-methylquinolinium or 5A1MQ.

Contains BPC-157 + MOTS-c + 5-Amino-1MQ + Tesamorelin

Sequence

Per component; the full sequences live on the component records and are not restated here. The three peptides are a 15-residue all-L free acid, a 16-residue mitochondrially encoded free acid and an N-acylated 44-residue amide. The fourth component contains no peptide bond anywhere in its structure, is a permanent cation, and is always shipped as a salt, so the counter-ion is part of the weighed article. Blend-relevant facts only: BPC-157 is H-GEPPPGKPADDAGLV-OH, free acid, no cysteine, no aromatic residue, four prolines at 3, 4, 5 and 8; MOTS-c is H-MRWQEMGYIFYPRKLR-OH free acid, methionines at 1 and 6 — not 1 and 5 — tryptophan at 3, tyrosines at 8 and 11; tesamorelin is the trans-3-hexenoyl-capped 44-mer amide, Met27 oxidation-labile. 5-amino-1MQ has no sequence and none is written: quinoline methylated at the ring nitrogen, giving a permanently charged quaternary center, with a primary amine at ring position 5. Tesamorelin is the active ingredient of EGRIFTA, also EGRIFTA SV and EGRIFTA WR, originated by Theratechnologies Inc. Under NDA 022505, approved 10 November 2010, with EGRIFTA WR approved 25 March 2025; the brand names are identity anchors for the 44-mer and state nothing about this article.

Molecular formula

Per component; a mixture has no combined formula and none is written. BPC-157 C62H98N16O22; MOTS-c C101H152N28O22S2 free acid; tesamorelin C221H366N72O67S free base, supplied as the acetate. 5-Amino-1MQ C10H11N2+ as the cation with the counter-ion excluded, C10H11IN2 as the iodide, C10H11ClN2 as the chloride, C10H11BrN2 as the bromide — and A formula cannot be stated for A lot until the supplier declares which, which no seller found does.

Average mass

Per component: BPC-157 1,419.556 Da; MOTS-c 2,174.621 Da; tesamorelin 5,135.856 Da free base, about 5,556.2 Da as the acetate. 5-Amino-1MQ 159.212 Da as the cation, 286.117 as the iodide, 194.66 as the chloride, 239.12 as the bromide. AT A nominal 10 mg each, 40 mg total, the three peptides give 7.04446, 4.59850 and 1.94710 micromol, a molar ratio of 3.62 : 2.36 : 1.00. The fourth component'S molar contribution cannot be stated at all: 10 mg is 62.809 micromol as the cation but 34.951 micromol as the iodide, a 1.80-fold indeterminacy, because iodide is 44.35 percent of the iodide salt by weight and a lot weighed as the iodide against a cation specification is 44 percent short of the stated substance.

Monoisotopic mass

Per component. BPC-157 1,418.7042, [M+H]+ 1,419.7115; MOTS-c 2,173.10774, [M+2H]2+ 1,087.56115; tesamorelin 5,132.71664, used with a deconvoluted charge envelope rather than a single-ion match. 5-Amino-1MQ 159.0917 as an observed ion — the atom-set monoisotopic 159.0922 less one electron mass, 0.00055 Da, written out because a permanent cation is observed as [M]+ and not as [M+H]+, which is the single most common reporting error on that component; the iodide is 285.9967. Separations that govern acceptance: des-acyl tesamorelin at -96.058 Da and the MOTS-c K14Q polymorph peptide at 2,173.07135, 0.03639 Da from the parent. No single blend molecular weight is printed.

Salt / variant note

(1) the salt fork on the small molecule, which is a variant question rather than an impurity question: cation 159.212, iodide 286.117, chloride 194.66, bromide 239.12 — four different weighed articles under one name. (2) MOTS-c neighbors: K14Q polymorph peptide 2,174.58, rat 20-mer 2,516.03, mouse 11-mer 1,446.75, the 1-12 fragment 1,620.91, the 1-13 fragment 1,777.10, mono-sulfoxide 2,190.62. (3) BPC-157 salt forms: the acetate and the arginate are separate records with different gross weights. (4) des-acyl tesamorelin at -96.058 Da, and the isobaric acyl isomers cis-3-hexenoyl and 2-hexenoyl. (5) Methionine sulfoxide at +15.995 Da on two components. (6) Ratio: 10 mg each is a stated nominal and no ratio is standard.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P1, P6 and P2 — panel definitionas a union, run per component and never once on the vial. P1 governs BPC-157 and MOTS-c. P6 governs the small molecule and inverts several defaults: it is achiral, so no chiral method is written for it and adding one by reflex is an error; qNMR is its primary net-content route rather than a fallback; and no specification is issued for it until the supplier declares the counter-ion. P2 governs tesamorelin's acyl group. No component is A metal complex, so qNMR remains available across the article. One consequence of a non-peptide component runs through the whole panel: it contributes nothing to amino acid analysis, needs no chiral method, is quantified by qNMR, and carries a counter-ion that leaves its share of a 40 mg fill between 5.57 mg and 10 mg of actual substance until the salt form is declared, so a certificate reporting a single total peptide content for this vial reports a sum in which one term is not a peptide. BPC-157 has no unique marker residue in this composition and its content comes by difference on proline rather than from a single marker

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Literature exists for each component and is graded on that component's record; none of it is literature about this mixture. The tesamorelin literature rests on registrational trials, by identifier: Falutz et al., N Engl J Med 2007;357:2359-2370, PMID 18057338, DOI 10.1056/NEJMoa072375; and Falutz et al., J Clin Endocrinol Metab 2010;95:4291-4304, PMID 20554713, DOI 10.1210/jc.2010-0490. No published study of this fixed four-component combination at any ratio has been identified, which is a statement about the search and not about the components.

4 Storage & specification

Storage

Co-lyophilized solid, stored at -20 degrees C plus or minus 5 degrees C, desiccated, protected from light, in Type I amber glass with nitrogen headspace. Non-sterile laboratory chemical. The controls are written against named residues rather than applied by habit: MOTS-c's two methionines, tryptophan and two tyrosines make it the most oxidation-labile component, tesamorelin adds Met27, and an iodide salt, if that is what the fourth component proves to be, is itself light-sensitive.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and light-protected. The retest-limiting attributes are oxidative and sit on the peptide side: methionine sulfoxide on two components, tryptophan oxidation products on MOTS-c, des-acyl tesamorelin at -96.058 Da. The small molecule, a stable aromatic quaternary salt, is expected to outlast all three and is monitored for the counter-ion and for halide exchange rather than for degradation.